How much weight loss can you expect from retatrutide at 3 months?

The Phase 2 obesity trial never reported a 12-week obesity endpoint — its earliest timepoint was 24 weeks. The closest real 3-month figure comes from an earlier phase 1b trial in type 2 diabetes, where the 12 mg dose produced roughly 10% mean weight reduction (8.96 kg) at 12 weeks. Because those 12 weeks are still inside the dose-escalation window, three months typically reflects an early, still-rising trajectory rather than a final result.

What were retatrutide's 24-week and 48-week results?

In the Phase 2 obesity trial (NEJM, 2023), the 12 mg group lost a mean of 17.5% of body weight at 24 weeks and 24.2% at 48 weeks, versus 1.6% and 2.1% on placebo. The curve had not clearly plateaued by week 48.

What percentage of people hit 10% or 15% weight loss on retatrutide?

At 48 weeks in the Phase 2 trial, among participants on 12 mg, 100% reached at least 5% loss, 93% reached at least 10%, and 83% reached at least 15%. On placebo the same thresholds were met by 27%, 9%, and 2%.

Do retatrutide 3-month results predict the final outcome?

Partly. The response is dose-dependent and the trial showed the steepest loss after steady state (roughly weeks 5-24), so an early three-month reading tends to understate the eventual result. A meaningful downward trend at 3 months is a better signal than the exact number, because most participants had not finished titrating.

Why do retatrutide before-and-after photos vary so much at 3 months?

Individual results scatter around the trial mean because of dose reached, titration speed, starting body weight, adherence, and normal biological variability. Photos also compress water shifts, lighting, and posture into a single frame, so they are a weaker signal than a consistent measured trend over the full titration.

How fast is weight loss per week on retatrutide?

Averaging the 12 mg group's ~17.5% at 24 weeks gives under 1% of body weight per week, but that mean hides a slow low-dose start and a faster middle once steady state and the target dose are reached. Week-to-week weight is noisy, so the trend matters more than any single week.

Retatrutide 3-Month Results: What ~10% at 12 Weeks Really Means (24.2% Comes Later)

If you are searching "retatrutide 3-month results," you are almost certainly trying to answer one question: is this working, or should I be worried? The honest answer starts with a caveat most before-and-after roundups skip — the pivotal retatrutide obesity trial did not report a three-month weight number at all. Its primary endpoint was measured at 24 weeks, and its headline at 48 weeks. ^[1] So any "3-month result" you read is either an early interim from a different trial, a community anecdote, or an interpolation. This guide gives you the real trial-anchored figures, explains why three months systematically understates the compound, and shows what a realistic 12-week reading looks like.

Everything here reports what the published clinical literature describes. None of it is medical advice, and retatrutide is not approved for human use.

Retatrutide results by timepoint: what the trials actually reported

The single most useful thing you can do is stop looking for one "retatrutide result" and start reading results by timepoint. The compound's effect builds over months, so the number is meaningless without a clock attached to it.

Retatrutide mean weight loss by timepoint (12 mg dose)

Timepoint	Mean weight loss (12 mg)	Source
12 weeks (~3 months)	~10% (8.96 kg) — phase 1b, type 2 diabetes	Phase 1b ^[3]
24 weeks (~6 months)	17.5%	Phase 2 obesity ^[1]
48 weeks (~11 months)	24.2%	Phase 2 obesity ^[1]
Placebo, 48 weeks	2.1%	Phase 2 obesity ^[1]

Read that column top to bottom and the shape of the answer appears: the three-month figure is roughly 40% of the way to the 48-week result. That is not a disappointing drug — it is a drug you are catching early. The Phase 2 obesity trial enrolled 338 adults and escalated the dose stepwise over the first ~12 weeks before holding it, which is exactly why the earliest obesity endpoint was set at 24 weeks rather than 12. ^[1]

A note on honesty: that 12-week figure is from a diabetes population, and weight loss tends to run somewhat smaller in type 2 diabetes than in obesity-only cohorts across this drug class. So it is a reasonable floor-ish reference for three months, not a guarantee. The cleaner framing is directional — at 12 weeks you are still climbing.

Why 3-month results understate retatrutide

Two mechanisms explain why the three-month reading is systematically lower than where a protocol ends up.

Titration. The clinical program did not start at the target dose. Participants ramped stepwise — with a 2 mg or 4 mg initial dose escalated every four weeks for up to 12 weeks — specifically to keep gastrointestinal effects tolerable. ^[1] For most of the first three months, exposure is below the dose that produced the headline numbers. You cannot get a 12 mg result while you are still at 4 mg.

Steady state. Retatrutide has a roughly six-day half-life, engineered through albumin binding so it can be dosed once weekly. ^[2] Plasma levels build over about four to five weeks before plateauing, so even at a fixed dose the early weeks understate the compound's true effect. Combine a rising dose with rising plasma levels and the first three months are, by design, the slow part of the curve.

This is why the Phase 2 trial reported its steepest rate of loss between roughly steady state and the 24-week endpoint, not in the first month. Reading week 8 or week 12 as the verdict is the most common way people talk themselves out of a working protocol. If yours looks stalled rather than merely slow, the retatrutide results-stalled guide walks through the real vs. apparent-plateau distinction.

Responder rates: how many people actually hit ≥10% and ≥15%?

Averages hide the more useful question — what fraction of people cross a meaningful threshold? This is where retatrutide's Phase 2 data are genuinely striking, because the response was not a wide spread hiding behind a good mean.

Responder rates at 48 weeks (Phase 2 obesity trial)

Threshold	8 mg	12 mg	Placebo
≥5% weight loss	100%	100%	27%
≥10% weight loss	93%	93%	9%
≥15% weight loss	75%	83%	2%

At 48 weeks, every participant on the 8 mg and 12 mg doses reached at least 5% loss, 93% reached at least 10%, and 83% of the 12 mg group reached at least 15%. ^[1] Against placebo rates of 27%, 9%, and 2%, the separation is large. Across all retatrutide doses pooled, the ≥5%, ≥10%, and ≥15% responder rates were 92%, 75%, and 60%. ^[1]

The catch for a three-month reader: these are 48-week responder rates. At 12 weeks, far fewer people have crossed the higher thresholds, because most of the loss is still ahead of them. A responder framing at three months should be read as "am I trending into responder territory," not "have I hit 15% yet."

Retatrutide weight loss per week: what a realistic pace looks like

People often search for a per-week number, so here is the honest arithmetic. If the 12 mg group averaged ~17.5% at 24 weeks, the average pace across those first 24 weeks is under 1% of body weight per week — but that average masks a slow start and a faster middle. ^[1] Early weeks on a low dose move little; the fastest stretch comes after titration completes and steady state is reached.

The typical three-month arc (illustrative of the trial pattern)

Phase	What tends to happen
Weeks 1-4 (low-dose ramp)	Appetite begins to ease; scale moves modestly. GI effects, if any, cluster here.
Weeks 5-8 (levels building)	Plasma levels approach steady state; effect becomes clearer.
Weeks 9-12 (dose still climbing)	Titration may still be in progress; loss accelerates but the "big" dose is often not yet reached.
End of month 3	An early, still-rising reading — below the 24-week and 48-week trial figures by design.

The takeaway is that a smooth downward trend at three months matters more than any single weekly figure. Week-to-week weight is noisy — water, sodium, and glycogen shifts routinely swamp a week of real fat loss. The week-by-week timeline breaks this arc down phase by phase.

Retatrutide before and after at 3 months: what's realistic

Before-and-after photos are the most-searched and least-reliable form of "results." They compress lighting, posture, hydration, pump, and time-of-day into a single frame, and the ones that circulate are self-selected toward the best responders. Here is how to read them honestly at the three-month mark.

Faces change first, visibly. Facial and neck fat often show early, which is why "retatrutide before and after face" is a common search — it is a real early signal, not vanity-specific.
The scale can outrun the mirror at 3 months. Twelve weeks of loss on a still-climbing dose may read clearly on a scale and a tape measure before it reads dramatically in a photo, especially at higher starting weights.
Water masks and unmasks fat loss. A whoosh after a stalled week is water redistribution, not sudden fat loss; both are normal.
Muscle matters for the "after." The trials paired the compound with lifestyle counseling; body composition — not just weight — shapes how a three-month photo actually looks. ^[1]

The point is not that photos are worthless — it is that a measured trend across the full titration is a stronger signal than any one frame, and three months is too early to judge a physique that is still being built.

Factors that affect your individual results

Individual outcomes scatter around the trial mean for reasons that are mostly predictable. The trial's dose-dependent design makes the first factor the biggest.

Dose reached. Results climbed in an orderly progression from 1 mg (−8.7% at 48 weeks) to 12 mg (−24.2%). ^[1] A protocol still at 4 mg at three months should not be compared to a 12 mg endpoint.
Titration speed. Escalating faster can worsen GI tolerability; escalating slower delays reaching the effective dose. The trial's stepwise schedule was the deliberate middle path. ^[1]
Starting body weight. Higher starting weight generally produces a larger absolute loss for a given percentage, changing how fast the mirror moves.
Adherence and consistency. Once-weekly dosing tolerates a missed dose without zeroing exposure (six-day half-life), but repeated gaps flatten the accumulation the compound depends on. ^[2]
Biological variability. Even in a controlled trial, responders spread across a range; the responder-rate data show most people cross meaningful thresholds, but not on identical timelines. ^[1]

Do 3-month results predict later loss?

Partly — and the direction is more predictive than the magnitude. Because the effect is dose-dependent and the steepest loss occurs after the first three months, an early reading tends to understate the eventual result rather than overstate it. ^[1] A participant trending steadily downward at 12 weeks, still climbing in dose, is on the trial's expected path.

What is not reassuring is a genuinely flat line once you are past steady state and at a stable target dose — that is the pattern worth investigating rather than waiting out, and it is the subject of the results-stalled guide. The nuance: at three months many people are neither clearly winning nor clearly stalled, because they have not yet reached the dose the headline numbers were measured on.

Retatrutide vs semaglutide and tirzepatide at comparable points

Cross-compound comparison is one of the top result-related searches, so here is the honest version — these come from separate trials with different populations and timepoints, not a head-to-head study.

Class comparison (separate trials, endpoint figures)

Compound	Receptors	Mean weight loss	Trial
Semaglutide	GLP-1	~15%	STEP 1 ^[5]
Tirzepatide	GLP-1 / GIP	~21%	SURMOUNT-1 ^[4]
Retatrutide	GLP-1 / GIP / glucagon	~24% (48 wk)	Phase 2 ^[1]

The stepwise pattern — more receptor coverage, more mean loss — is what the triple-agonist thesis predicts, but note the timeframes differ (semaglutide and tirzepatide endpoints run longer than 48 weeks). At the three-month mark specifically, all three are still in or near titration, so early differences between them are smaller and noisier than the endpoint gaps suggest. Judging any of them at 12 weeks flatters none of them.

Common reasons 3-month results disappoint (and what they usually mean)

Most "retatrutide not working at 3 months" reports resolve to one of a few explanations, and few of them are the compound failing.

Reading month one as the verdict. Levels are still building for ~4-5 weeks; early weeks understate the effect by design. ^[2]
Comparing to a dose you're not on yet. Expecting a 12 mg (−24.2%) outcome while still titrating through 4 mg is the single most common mismatch. ^[1]
Water noise on the scale. A flat or up week inside a downtrend is usually fluid, not fat regain.
Handling and reconstitution errors. Foaming, shaking, or freeze-thaw degrade the peptide before it acts, adding variability that looks like a weak response.
Sourcing quality. An under-concentrated or mislabeled vial produces a real but muted effect; a batch-matched certificate of analysis is what keeps the label honest to the contents.

I went in expecting the numbers I'd seen quoted online — the big 24% figure — and I made the classic mistake of putting my three-month check-in next to it. On paper that looked like a failure. It wasn't. I was still finishing titration at the twelve-week mark, so I was reading an early, half-dosed result against a full-dose, eleven-month endpoint.

Once I lined my own data up against the trial by timepoint, it made sense. My three-month loss sat close to the ~10% the phase 1b trial reported at twelve weeks, and the curve was still pointing down, not flattening. The pharmacokinetics said steady state around week five, so I stopped treating any single week as signal and watched the trend across the whole ramp instead.

The unglamorous lesson was patience plus bookkeeping. Dated vials, gentle reconstitution, one weigh-in cadence, and a chart with weeks on the x-axis. Three months in, the honest read was "on track and still climbing" — which is exactly what the trial arc predicts, and nothing like the plateau I'd have panicked about if I'd only compared myself to the finish line.

— Alyssa Brennan, Nashville, TN

Frequently asked questions

How much weight loss can you expect from retatrutide at 3 months?: The Phase 2 obesity trial never reported a 12-week obesity endpoint — its earliest timepoint was 24 weeks. The closest real 3-month figure comes from an earlier phase 1b trial in type 2 diabetes, where the 12 mg dose produced roughly 10% mean weight reduction (8.96 kg) at 12 weeks. Because those 12 weeks fall inside the dose-escalation window, three months typically reflects an early, still-rising trajectory rather than a final result.
What were retatrutide's 24-week and 48-week results?: In the Phase 2 obesity trial (NEJM, 2023), the 12 mg group lost a mean of 17.5% of body weight at 24 weeks and 24.2% at 48 weeks, versus 1.6% and 2.1% on placebo. The curve had not clearly plateaued by week 48.
What percentage of people hit 10% or 15% weight loss on retatrutide?: At 48 weeks in the Phase 2 trial, among participants on 12 mg, 100% reached at least 5% loss, 93% reached at least 10%, and 83% reached at least 15%. On placebo the same thresholds were met by 27%, 9%, and 2%.
Do retatrutide 3-month results predict the final outcome?: Partly. The response is dose-dependent and the trial showed the steepest loss after steady state (roughly weeks 5-24), so an early three-month reading tends to understate the eventual result. A meaningful downward trend at 3 months is a better signal than the exact number, because most participants had not finished titrating.
Why do retatrutide before-and-after photos vary so much at 3 months?: Individual results scatter around the trial mean because of dose reached, titration speed, starting body weight, adherence, and normal variability. Photos also compress water shifts, lighting, and posture into a single frame, so they are a weaker signal than a consistent measured trend over the full titration.
How fast is weight loss per week on retatrutide?: Averaging the 12 mg group's ~17.5% at 24 weeks gives under 1% of body weight per week, but that mean hides a slow low-dose start and a faster middle once steady state and the target dose are reached. Week-to-week weight is noisy, so the trend matters more than any single week.

Glossary

Titration: Stepwise dose escalation over weeks — here up to ~12 weeks — to improve tolerability as exposure accumulates. Most of the first three months is spent below the target dose.
Steady state: The point at which plasma drug levels plateau on repeat dosing — roughly 4-5 weeks for retatrutide's ~6-day half-life. Readings before it understate the effect.
Responder rate: The percentage of participants crossing a weight-loss threshold (e.g. ≥10% or ≥15%), a more informative figure than the group mean.
Least-squares mean: A model-adjusted average used in trials to estimate the typical treatment effect; the source of the −17.5% and −24.2% figures.
Half-life: The time for plasma concentration to fall by half. Retatrutide's ~6-day half-life supports once-weekly dosing and slow accumulation.
Placebo-adjusted: A result stated relative to the placebo group, isolating the drug's contribution from diet, counseling, and regression to the mean.

References

Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526.
Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: preclinical and clinical characterization. Cell Metabolism. 2022;34(9):1234-1247.
Urva S, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b trial. The Lancet. 2022;400(10366):1869-1881.
Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205-216.
Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002.

For research and educational purposes only. Not medical advice. Trial figures describe published clinical studies; cross-compound comparisons and the 12-week figure are drawn from separate trials and populations, not a single head-to-head obesity study. Retatrutide is investigational and is not approved for human use.